Effects of prolonged exendin-4 administration on hypothalamic-pituitary-adrenal axis activity and water balance

American Journal of Physiology - Endocrinology and Metabolism

Volumn 304, Issue 10, 2013, Pages

  Gil Lozano, Manuel ^a,b   Romaní Pérez, Marina ^a   Outeiriño Iglesias, Verónica ^a   Vigo, Eva ^a   Brubaker, Patricia L ^b   González Matías, Lucas C ^a   Mallo, Federico ^a  

^a UNIVERSITY OF VIGO   (Spain)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adrenal; Circadian; Corticosterone; Diuresis; Exendin 4

Indexed keywords

EXENDIN 4; GLUCOCORTICOID;

ADRENAL CORTEX ATROPHY; ADRENAL GLAND; ADRENALECTOMY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHRONIC STRESS; CONTROLLED STUDY; DIURESIS; FLUID BALANCE; FOOD INTAKE; HORMONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; URINARY EXCRETION;

ADRENAL; CIRCADIAN; CORTICOSTERONE; DIURESIS; EXENDIN-4;

ADRENAL GLANDS; ADRENOCORTICOTROPIC HORMONE; ANIMALS; BODY WEIGHT; CIRCADIAN RHYTHM; CORTICOSTERONE; EATING; GLUCAGON-LIKE PEPTIDE 1; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; PEPTIDES; PITUITARY-ADRENAL SYSTEM; RATS; RATS, SPRAGUE-DAWLEY; STRESS, PHYSIOLOGICAL; VENOMS; WATER-ELECTROLYTE BALANCE;

EID: 84878565404     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00529.2012     Document Type: Article

References (75)

1. Akana SF, Scribner KA, Bradbury MJ, Strack AM, Walker CD, Dallman MF. Feedback sensitivity of the rat hypothalamo-pituitaryadrenal axis and its capacity to adjust to exogenous corticosterone. Endocrinology 131: 585-594, 1992.
2. Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Lond) 96: 513-523, 1999.
3. Barragán JM, Eng J, Rodríguez R, Blázquez E. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am J Physiol Endocrinol Metab 277: E784-E791, 1999.
4. Baylis C, Handa RK, Sorkin M. Glucocorticoids and control of glomerular filtration rate. Semin Nephrol 10: 320-329, 1990.
5. Chan O, Chan S, Inouye K, Vranic M, Matthews SG. Molecular regulation of the hypothalamo-pituitary-adrenal axis in streptozotocininduced diabetes: effects of insulin treatment. Endocrinology 142: 4872-4879, 2001.
6. Chan O, Inouye K, Vranic M, Matthews SG. Hyperactivation of the hypothalamo-pituitary-adrenocortical axis in streptozotocin-diabetes is associated with reduced stress responsiveness and decreased pituitary and adrenal sensitivity. Endocrinology 143: 1761-1768, 2002.
7. Checkley S. The neuroendocrinology of depression and chronic stress. Br Med Bull 52: 597-617, 1996.
8. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
9. Drucker DJ. The biology of incretin hormones. Cell Metab 3: 153-165, 2006.
10. Drucker DJ, Nauck AN. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-1705, 2006.
11. Dunphy JL, Taylor RG, Fuller PJ. Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression. Mol Cell Endocrinol 141: 179-186, 1998.
12. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, Bland RJ, Klugmann M, Banks WA, Drucker DJ, Haile CN. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 9: 1173-1179, 2003.
13. Engeland WC, Ennen WB, Elayaperumal A, Durand DA, Levay-Young BK. Zone-specific cell proliferation during compensatory adrenal growth in rats. Am J Physiol Endocrinol Metab 288: E298-E306, 2005.
14. Ennen WB, Levay-Young BK, Engeland WC. Zone-specific cell proliferation during adrenocortical regeneration after enucleation in rats. Am J Physiol Endocrinol Metab 289: E883-E891, 2005.
15. Gadek-Michalska A, Bugajski J. Repeated handling, restraint, or chronic crowding impair the hypothalamic-pituitary-adrenocortical response to acute restraint stress. J Physiol Pharmacol 54: 449-459, 2003.
16. Gao W, Jusko WJ. Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans. Drug Metab Dispos 40: 990-997, 2012.
17. Gardner DG, Hane S, Trachewsky D, Schenk D, Baxter JD. Atrial natriuretic peptide mRNA is regulated by glucocorticoids in vivo. Biochem Biophys Res Commun 139: 1047-1054, 1986.
18. Gedulin BR, Nikoulina SE, Smith PA, Gedulin G, Nielsen LL, Baron AD, Parkes DG, Young AA. Exenatide (exendin-4) improves insulin sensitivity and (beta)-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 146: 2069-2076, 2005.
19. Gibson MJ, DeNicola AF, Krieger DT. Streptozotocin-induced diabetes is associated with reduced immunoreactive beta-endorphin concentrations in neurointermediate pituitary lobe and with disrupted circadian periodicity of plasma corticosterone levels. Neuroendocrinology 41: 64-71, 1985.
20. Gil-Lozano M, Pérez-Tilve D, Alvarez-Crespo M, Martís A, Fernandez AM, Catalina PA, Gonzalez-Matias LC, Mallo F. GLP-1(7-36)-amide and exendin-4 stimulate the HPA axis in rodents and humans. Endocrinology 151: 2629-2640, 2010.
21. Gotthardt M, Lalyko G, van Eerd-Vismale J, Keil B, Schurrat T, Hower M, Laverman P, Behr TM, Boerman OC, Göke B, Béhé M. A new technique for in vivo imaging of specific GLP-1 binding sites: first results in small rodents. Regul Pept 137: 162-167, 2006.
22. Gutzwiller JP, Hruz P, Huber AR, Hamel C, Zehnder C, Drewe J, Gutmann H, Stanga Z, Vogel D, Beglinger C. Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. Digestion 73: 142-150, 2006.
23. Gutzwiller JP, Tschopp S, Bock A, Zehnder CE, Huber AR, Kreyenbuehl M, Gutmann H, Drewe J, Henzen C, Goeke B, Beglinger C. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 89: 3055-3061, 2004.
24. Holsboer F, Barden N. Antidepressants and hypothalamic-pituitaryadrenocortical regulation. Endocr Rev 17: 187-205, 1996.
25. Holst JJ. The physiology of glucagon-like peptide-1. Physiol Rev 87: 1409-1439, 2007.
26. Jin SLC, Han VKM, Simmons JE, Towle AC, Lander JM, Lund PK. Distribution of glucagon-like peptide I, glucagon and glicentin in the rat brain: an inmunocytochemical study. J Comp Neurol 271: 519-532, 1988.
27. Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 27: 313-318, 2003.
28. Kenyon CJ, Saccoccio NA, Morris DJ. Glucocorticoid inhibition of mineralocorticoid action in the rat. Clin Sci (Lond) 67: 329-335, 1984.
29. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 20: 876-913, 1999.
30. Kinzig KP, D'Alessio DA, Herman JP, Sakai RR, Vahl TP, Figueiredo HF, Murphy EK, Seeley RJ. CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors. J Neurosci 23: 6163-6170, 2003.
31. Konarska M, Stewart RE, McCarty R. Habituation of sympatheticadrenal medullary responses following exposure to chronic intermittent stress. Physiol Behav 45: 255-261, 1989.
32. Lachey JL, D'Alessio DA, Rinaman L, Elmquist JK, Drucker DJ, Seeley RJ. The role of central glucagon-like peptide-1 in mediating the effects of visceral illness: differential effects in rats and mice. Endocrinology 146: 458-462, 2005.
33. Larsen PJ, Tang-Christensen M, Holst JJ, Orskov C. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 77: 257-270, 1997.
34. Larsen PJ, Tang-Christensen M, Jessop DS. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 138: 4444-4455, 1997.
35. Malendowicz LK, Neri G, Nussdorfer GG, Nowak KW, Zyterska A, Ziolkowska A. Prolonged exendin-4 administration stimulates pituitaryadrenocortical axis of normal and streptozotocin-induced diabetic rats. Int J Mol Med 12: 593-596, 2003.
36. Malendowicz LK, Spinazzi R, Nussdorfer GG, Trejter M. Effects of preproglucagon-derived peptides and exendins on steroid-hormone secretion from dispersed adrenocortical cells of normal and streptozotocininduced diabetic rats. Int J Mol Med 12: 115-119, 2003.
37. McCall AL. The impact of diabetes on the CNS. Diabetes 41: 557-570, 1992.
38. McKay NJ, Kanoski SE, Hayes MR, Daniels D. Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake. Am J Physiol Regul Integr Comp Physiol 301: R1755-R1764, 2011.
39. Meijer OC, Van Oosten RV, De Kloet ER. Elevated basal trough levels of corticosterone suppress hippocampal 5-hydroxytryptamine(1A) receptor expression in adrenally intact rats: implication for the pathogenesis of depression. Neuroscience 80: 419-426, 1997.
40. Miśkowiak B, Kasprzak A, Malendowicz LK. Comparative stereological studies on the effects of long term CRF and ACTH treatment on the cortex of the suprarenal gland. J Anat 146: 167-172, 1986.
41. Moreno C, Mistry M, Roman RJ. Renal effects of glucagon-like peptide in rats. Eur J Pharmacol 434: 163-167, 2002.
42. Musselman DL, Betan E, Larsen H, Phillips LS. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry 54: 317-329, 2003.
43. Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc 49, Suppl 1: S16-S29, 2009.
44. Orskov C, Poulsen SS, Møller M, Holst JJ. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 45: 832-835, 1996.
45. Ostrander MM, Ulrich-Lai YM, Choi DC, Richtand NM, Herman JP. Hypoactivity of the hypothalamo-pituitary-adrenocortical axis during recovery from chronic variable stress. Endocrinology 147: 2008-2017, 2006.
46. Pérez-Tilve D, González-Matías L, Aulinger BA, Alvarez-Crespo M, Gil-Lozano M, Alvarez E, Andrade-Olivie AM, Tschöp MH, D'Alessio DA, Mallo F. Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system. Am J Physiol Endocrinol Metab 298: E1088-E1096, 2010.
47. Rabasa C, Muñoz-Abellán C, Daviu N, Nadal R, Armario A. Repeated exposure to immobilization or two different footshock intensities reveals differential adaptation of the hypothalamic-pituitary-adrenal axis. Physiol Behav 103: 125-133, 2011.
48. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 22: 659-661, 2008.
49. Richter CP. Increased salt appetite in adrenalectomized rats. Am J Physiol 115: 155-161, 1936.
50. Rinaman L. Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus. Am J Physiol Regul Integr Comp Physiol 277: R582-R590, 1999.
51. Rivier C, Vale W. Effect of the long-term administration of corticotropinreleasing factor on the pituitary-adrenal and pituitary-gonadal axis in the male rat. J Clin Invest 75: 689-694, 1985.
52. Roy M, Collier B, Roy A. Hypothalamic-pituitary-adrenal axis dysregulation among diabetic out-patients. Psychiatry Res 31: 31-37, 1990.
53. Rubin RT, Phillips JJ, McCracken JT, Sadow TF. Adrenal gland volume in major depression: relationship to basal and stimulated pituitaryadrenal cortical axis function. Biol Psychiatry 40: 89-97, 1996.
54. Sapolsky RM, Romero LM, Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev 21: 55-89, 2000.
55. Sarabdjitsingh RA, Isenia S, Polman A, Mijalkovic J, Lachize S, Datson N, de Kloet ER, Meijer OC. Disrupted corticosterone pulsatile patterns attenuate responsiveness to glucocorticoid signaling in rat brain. Endocrinology 151: 1177-1186, 2010.
56. Sarkar S, Fekete C, Légrádi G, Lechan RM. Glucagon like peptide 1 (7-36)-amide nerve terminals densely innervate corticotrophin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Brain Res 985: 163-168, 2003.
57. Schlatter P, Beglinger C, Drewe J, Gutmann H. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept 141: 120-128, 2007.
58. Shughrue PJ, Lane MV, Merchenthaler I. Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus. Endocrinology 137: 5159-5162, 1996.
59. Simonsen L, Holst JJ, Deacon CF. Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs. Diabetologia 49: 706-712, 2006.
60. Stark E, Kárteszi M, Rappay G, Makara GB. Effects of treatment with adrenocorticotrophin on the hypothalamo-pituitary-adrenal system. J Endocrinol 88: 131-139, 1981.
61. Tang-Christensen M, Vrang N, Larsen PJ. Glucagon-like peptide 1(7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. Diabetes 47: 530-537, 1998.
62. Tauchi M, Zhang R, D'Alessio DA, Seeley RJ, Herman JP. Role of central glucagon-like peptide-1 in hypothalamo-pituitary-adrenocortical facilitation following chronic stress. Exp Neurol 210: 458-466, 2008.
63. Tauchi M, Zhang R, D'Alessio DA, Stern JE, Herman JP. Distribution of glucagon-like peptide-1 immunoreactivity in the hypothalamic paraventricular and supraoptic nuclei. J Chem Neuroanat 36: 144-149, 2008.
64. Thorens B, Porret A, Büler L, Deng SP, Morel P, Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 42: 1678-1682, 1993.
65. Thunhorst RL, Beltz TG, Johnson AK. Glucocorticoids increase salt appetite by promoting water and sodium excretion. Am J Physiol Regul Integr Comp Physiol 293: R1444-R1451, 2007.
66. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR. A role for glucagon-like peptide 1 in the central regulation of feeding. Nature 379: 69-72, 1996.
67. Ulrich-Lai YM, Arnhold MM, Engeland WC. Adrenal splanchnic innervation contributes to the diurnal rhythm of plasma corticosterone in rats by modulating adrenal sensitivity to ACTH. Am J Physiol Regul Integr Comp Physiol 290: R1128-R1135, 2006.
68. Vahl TP, Ulrich-Lai YM, Ostrander MM, Dolgas CM, Elfers EE, Seeley RJ, D'Alessio DA, Herman JP. Comparative analysis of ACTH and corticosterone sampling methods in rats. Am J Physiol Endocrinol Metab 289: E823-E828, 2005.
69. Vrang N, Hansen M, Larsen PJ, Tang-Christensen M. Characterization of brainstem preproglucagon projections to the paraventricular and dorsomedial hypothalamic nuclei. Brain Res 1149: 118-126, 2007.
70. Weitzman ED, Fukushima D, Nogeire C, Roffwarg H, Gallagher TF, Hellman L. Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects. J Clin Endocrinol Metab 33: 14-22, 1971.
71. Wilkinson CW, Shinsako J, Dallman MF. Return of pituitary-adrenal function after adrenal enucleation or transplantation: diurnal rhythms and responses to ether. Endocrinology 109: 162-169, 1981.
72. Windle RJ, Wood SA, Shanks N, Lightman SL, Ingram CD. Ultradian rhythm of basal corticosterone release in the female rat: dynamic interaction with the response to acute stress. Endocrinology 139: 443-450, 1998.
73. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, Hollenberg AN, Baggio L, Saper CB, Drucker Elmquist JK. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 110: 43-52, 2002.
74. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M. Glucose-lowering and insulin-sensitizing actions of exendin-4. Studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys, Maccaca mulata. Diabetes 48: 1026-1034, 1999.
75. Zelena D, Filaretova L, Mergl Z, Barna I, Tóth ZE, Makara GB. Hypothalamic paraventricular nucleus, but not vasopressin, participates in chronic hyperactivity of the HPA axis in diabetic rats. Am J Physiol Endocrinol Metab 290: E243-E250, 2006.